Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis.
Cladribine
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
Daclizumab for relapsing remitting multiple sclerosis.
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Genzyme’s Lemtrada Recommended for Reimbursement on NHS by the National Institute for Health and Care Excellence (NICE)
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-β Production in Neurons.
EFNS 2012
Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes.
Food and Drug Administration drug insert for Campath (alemtuzumab)
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.
Antiinflammatory effects of orientin-2″-o-galactopyranoside on lipopolysaccharide-stimulated microglia.
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
Gustatory Dysfunction in Multiple Sclerosis
Testing for urinary tract colonisation before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation.
Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
Acorda Therapeutics announces issuance of additional U.S. Patent for AMPYRA® covering a range of dosage strengths
Rituximab for refractory digital infarcts and ulcers in systemic sclerosis.
Tumefactive Multiple Sclerosis presenting as Acute Ischemic Stroke.
Roche's MabThera approved for two vasculitis indications in UK
Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review.
Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.

Pages